NEW YORK, March 2, 2026 — Leads & Copy — Immuneering Corporation (Nasdaq: IMRX) will present at the Leerink Global Healthcare Conference in Miami, Florida, from March 9-11, 2026.
Ben Zeskind, Chief Executive Officer, will discuss the company’s pipeline, platform, and business strategy during a fireside chat and 1×1 investor meetings.
The fireside chat is scheduled for Monday, March 9, 2026, from 3:40 – 4:10 pm ET.
A live webcast of the presentation will be available in the Investor Relations section of Immuneering’s website.
Immuneering is a late-stage clinical oncology company focused on developing cancer medicines, called Deep Cyclic Inhibitors, designed to improve overall survival. These medicines aim to shrink tumors, preserve body mass, and minimize side effects.
Immuneering’s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve survival across many cancer indications, including MAPK pathway-driven tumors such as pancreatic cancer. The company expects to dose the first patient in mid-2026 in MAPKeeper 301, a globally randomized pivotal Phase 3 trial evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients.
The Company’s development pipeline also includes additional combination opportunities and early-stage programs.
Source: Immuneering Corporation
